Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Working Capital Changes (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Other Working Capital Changes for 4 consecutive years, with -$109000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Working Capital Changes rose 98.5% year-over-year to -$109000.0, compared with a TTM value of -$12.5 million through Sep 2025, down 964.7%, and an annual FY2024 reading of -$11.1 million, down 7882.39% over the prior year.
  • Other Working Capital Changes was -$109000.0 for Q2 2025 at Atara Biotherapeutics, down from $110000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $8.7 million in Q3 2024 and bottomed at -$12.5 million in Q4 2024.
  • Average Other Working Capital Changes over 4 years is -$1.5 million, with a median of -$102000.0 recorded in 2023.
  • Peak annual rise in Other Working Capital Changes hit 96177.78% in 2024, while the deepest fall reached 54317.39% in 2024.
  • Year by year, Other Working Capital Changes stood at -$1.2 million in 2022, then soared by 101.87% to $23000.0 in 2023, then plummeted by 54317.39% to -$12.5 million in 2024, then skyrocketed by 99.13% to -$109000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for ATRA at -$109000.0 in Q2 2025, $110000.0 in Q1 2025, and -$12.5 million in Q4 2024.